JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans.

Saved in:
Bibliographic Details
Title: JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans.
Authors: Fourie AM; Janssen Research & Development, LLC, La Jolla, CA, USA. afourie@its.jnj.com., Cheng X; Protagonist Therapeutics, Newark, CA, USA., Chang L; Janssen Research & Development, LLC, La Jolla, CA, USA., Greving C; Janssen Research & Development, LLC, La Jolla, CA, USA., Li X; Janssen Research & Development, LLC, La Jolla, CA, USA., Knight B; Janssen Research & Development, LLC, La Jolla, CA, USA., Polidori D; Janssen Research & Development, LLC, La Jolla, CA, USA., Patrick A; Janssen Research & Development, LLC, Spring House, PA, USA., Bains T; Janssen Research & Development, LLC, Spring House, PA, USA., Steele R; Janssen Research & Development, LLC, Spring House, PA, USA., Allen SJ; Janssen Research & Development, LLC, Spring House, PA, USA., Patch RJ; Janssen Research & Development, LLC, Spring House, PA, USA., Sun C; Janssen Research & Development, LLC, Spring House, PA, USA., Somani S; Janssen Research & Development, LLC, Spring House, PA, USA., Bhandari A; Protagonist Therapeutics, Newark, CA, USA., Liu D; Protagonist Therapeutics, Newark, CA, USA., Huie K; Protagonist Therapeutics, Newark, CA, USA., Li S; Protagonist Therapeutics, Newark, CA, USA., Rodriguez MA; Janssen Research & Development, LLC, La Jolla, CA, USA., Xue X; Janssen Research & Development, LLC, La Jolla, CA, USA., Kannan A; Janssen Research & Development, LLC, La Jolla, CA, USA., Kosoglou T; Janssen Research & Development, LLC, Spring House, PA, USA., Sherlock JP; Janssen Research & Development, LLC, Spring House, PA, USA., Towne J; Janssen Research & Development, LLC, La Jolla, CA, USA., Holland MC; Janssen Research & Development, LLC, Spring House, PA, USA., Modi NB; Protagonist Therapeutics, Newark, CA, USA.
Source: Scientific reports [Sci Rep] 2024 Jul 30; Vol. 14 (1), pp. 17515. Date of Electronic Publication: 2024 Jul 30.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2045-2322
DOI:10.1038/s41598-024-67371-5